Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats.

@article{Callaway1999DelayedTW,
  title={Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats.},
  author={Jennifer K. Callaway and M. J. Knight and Dr. P. J. Watkins and Philip M. Beart and Bevyn Jarrott},
  journal={Stroke},
  year={1999},
  volume={30 12},
  pages={2704-12; discussion 2712}
}
BACKGROUND AND PURPOSE AM-36 is a novel arylalkylpiperazine with combined antioxidant and Na(+) channel blocking actions. Individually, these properties have been shown to confer neuroprotection in a variety of in vitro and in vivo animal models of stroke. Preliminary studies have shown that AM-36 is neuroprotective in vivo. The purpose of the present study was to assess the neuroprotective and behavioral outcome after delayed administration of AM-36 in an endothelin-1-induced, middle cerebral… CONTINUE READING
23 Citations
2 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-2 of 2 references

6-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats

  • CG Markgraf, L Nelson, +6 authors MD. Linnik
  • Stroke
  • 1998

Similar Papers

Loading similar papers…